ClinicalTrials.gg
RecruitingNCT05855759MODAUpdated Feb 19, 2026

Acellular Matrix From Human Dermis in Combination With Orthobiologic Stimuli for Augmentation of Massive Rotator Cuff Tears

An interventional study of Acellular Dermal Matrix and Acellular Dermal Matrix with autologous orthobiologics in Rotator Cuff Tears, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Rotator Cuff Injuries with a site in Italy — 8 open to participants now, 8 under way, none of them phase 3. Rotator Cuff Injuries · Italy.

Planned enrollment
5th of 14
72 · median 49
Started
2023
the only one that year
No phase
14 of 20
5 open now
Registered
13th of 20
by date
Lead sponsor
6 of 20
Istituto Ortopedico Rizzoli

Among the 20 studies in Rotator Cuff Injuries with a site in Italy, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 14 with no phase, and was the 13th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

8 of the 20 studies in Rotator Cuff Injuries with a site in Italy are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Rotator Cuff Injuries with a site in Italy, or all of them as a file.
02

Study summary

The use of biologic acellular matrices for the surgical augmentation of rotator cuff lesions has greatly expanded inrecent years. The study team patented a method for removing cells from human dermis (Acellular Dermal Matrix), maintaining unaltered biological and structural integrity. Acellular Dermal Matrix has been succesfully used for rotator cuff surgical repair augmentation beside in a limited number of patients. The aim of the project is to demonstrate the therapeutical efficacy of this strategy in patients affected by rotator cuff massive tears. Acellular Dermal Matrix will be also combined with autologous orthobiologics.

03

Conditions studied

  • Rotator Cuff Tears

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients affected by large to massive lesion according to Gerber involving supraspinatus and infraspinatus tendons
  • tendon retraction \<=3 according to Thomazeau
  • fatty degeneration \<=3 according to Goutallier
  • possibility to obtain tendon reduction,
  • pre-operative Magnetic Resonance Imaging,
  • ability to read, understand and complete outcome scores

Exclusion criteria

Exclusion Criteria:

  • patients affected by osteoarthritic degeneration,
  • frozen shoulder,
  • symptomatic acromioclavicular arthritis,
  • revision surgeries,
  • inability to cope with post-operative rehabilitation regimen,
  • connective tissue disease,
  • current or past hematologicaldisorders,
  • comorbidities affecting healing,
  • active infections,
  • cancers,
  • pregnancy and lactation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    Acellular Dermal Matrix

    Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix

    Other: Acellular Dermal Matrix

  • Experimental
    Acellular Dermal Matrix with autologous orthobiologics

    Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix with orthobiologics autologous: humeral bone marrow concentrate and subacromial bursa

    Other: Acellular Dermal Matrix with autologous orthobiologics

Interventions

  • OtherAcellular Dermal Matrix

    Patinets will be treated with acellular dermal matrix with standard arthroscopic technique performed as per normal clinical practice. For the tendon repair the acellular dermal matrix patch will be placed over the repaired tendon with dedicated sutures and anchors.

  • OtherAcellular Dermal Matrix with autologous orthobiologics

    Patinets will be treated with acellular dermal matrix enriched with autologous humeral bone marrow concentrate and subacromial bursa with standard arthroscopic technique. Humeral bone marrow concentrate will be harvested from the proximal humeral head inthe operating room and concentrated by an automatic close system.

06

What researchers measure

Primary outcomes

  1. re-tear rate

    Presence/absence of re-tear on magnetic resonance imaging

    Time frame: 12 months after surgery

Secondary outcomes

  1. cell yeld

    number of stromals cells contained in the humeral bone marrow concentrate

    Time frame: baseline

  2. subacromial bursa

    Half of the subacromial bursal tissue wll be assessed for determining the cell yield (number of stromal cells contained for mg of tissue) and half for histological processing

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Rotini R, Marinelli A, Guerra E, Bettelli G, Castagna A, Fini M, Bondioli E, Busacca M. Human dermal matrix scaffold augmentation for large and massive rotator cuff repairs: preliminary clinical and MRI results at 1-year follow-up. Musculoskelet Surg. 2011 Jul;95 Suppl 1:S13-23. doi: 10.1007/s12306-011-0141-8. PubMed 21691735 ↗
  • Bondioli E, Fini M, Veronesi F, Giavaresi G, Tschon M, Cenacchi G, Cerasoli S, Giardino R, Melandri D. Development and evaluation of a decellularized membrane from human dermis. J Tissue Eng Regen Med. 2014 Apr;8(4):325-36. doi: 10.1002/term.1530. Epub 2012 Jun 11. PubMed 22689414 ↗
  • Cavallo M, Solaro L, Tortorella F, Brunello V, Melandri D, Pagani S, Martini L, Guerra E, Tschon M. Acellular dermal matrix alone or in combination with subacromial bursa and humeral bone marrow concentrate for augmentation of massive rotator cuff tear repair: a double-blind randomized controlled trial protocol (MODA). Front Med (Lausanne). 2026 Mar 6;13:1724038. doi: 10.3389/fmed.2026.1724038. eCollection 2026. PubMed 41868235 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jul 2025, 19 months.

Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's 19 months is close to that.

Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
May 11, 2023
StartActual
Dec 18, 2023
Primary completionActual
Jul 30, 2025
CompletionEst.
May 30, 2026
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05855759
Responsible party
Sponsor
First posted
May 11, 2023
Start date
Dec 18, 2023
Primary completion
Jul 30, 2025
Completion
May 30, 2026 (estimated)
Last update
Feb 19, 2026

Study contacts

Marco Cavallo, MD
Contact
marco.cavallo@ior.it
0039.051.63.66 ext. 927
Matilde Tschon, BSC
Contact
matilde.tschon@ior.it
0039051.63.66 ext. 472

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion